ARTICLE | Emerging Company Profile
Actym: programming microbes to treat solid tumors
Backed by Boehringer Ingelheim and Panacea, Actym is engineering microbes to enable safe, systemic delivery
June 2, 2023 10:38 PM UTC
Actym is delivering immunomodulatory payload combinations to solid tumors using a modified bacterial vector that naturally enriches in the tumor microenvironment after systemic delivery.
Actym Therapeutics Inc. co-founder, President and CEO Christopher Thanos told BioCentury the company wanted to develop technology that can target immunologically cold tumors, enable multi-pathway target engagement, and be systemically administered while still specifically targeting the tumor...